Chemical Hygiene Plan Table of Contents Section Page 1

Total Page:16

File Type:pdf, Size:1020Kb

Chemical Hygiene Plan Table of Contents Section Page 1 University of Maine at Presque Isle: Chemical Hygiene Plan Table of Contents Section Page 1. Introduction: I. Purpose and Scope 3 II. Responsibilities 3 III. Lab Safety Plan 5 IV. Emergency Numbers 5 2. Lab Safety Plan 7 Purpose 7 Safe Work Practices 8 Hazard Awareness Policy 8 General Safety Practices 8 A. When to use a laboratory ventilation hood 9 B. When to use safety shields or other containment devices 10 C. When to use personal protective equipment 10 D. When to institute special work practices: particularly 11 hazardous substances Laboratory Safety Equipment 12 Required Approvals 14 Medical Consultation and Examination 15 Campus Contacts 17 Employee Information and Training 18 Laboratory Plan Training Documentation 19 Student Safety Agreements and Chemical Hygiene Information 20 Sheets Review and Update of Chemical Hygiene Plan 26 3. General Emergency Procedures 27 4. Standard Operating Procedures: List of Appendices 37 Appendix A: A-1 General Procedures for Safe Laboratory Practice 38 A-2 Protective Apparel for the Laboratory 44 A-3 Safety Equipment for the Laboratory 47 A-4 Electrical Equipment in the Laboratory 56 A-5 Working with Acutely Toxic, Chronically Toxic and Corrosive 64 Substances A-6 Handling Flammable and Explosive Substances 75 A-7 Ordering and Procurement of Chemicals 89 A-8 Storing Chemicals in Storerooms or Stockrooms 90 A-9 Distributing Chemicals from Stockrooms to Laboratories 94 A-10 Storing Chemicals in Laboratories 96 A-11 Handling Spills 99 1 A-12 Small-Scale Mercury Spill Response Procedure 103 A-13 High and Low Pressure Experiments 105 A-14 Handling of Compressed Gases 108 Appendix B. Center for Disease Control (CDC) Guidelines for work 117 using infectious agents and managing biohazardous waste are incorporated by reference into this laboratory safety plan. Appendix C: Hazard Communication Program (UMPI Security) is incorporated by reference into this laboratory safety plan. Appendix D: Use and Types of Laboratory Hoods 118 Appendix I: Hazardous Waste Disposal 121 Appendix Z: Emergency Phone Contacts 129 Additional appendices in separate file: Appendix E: Testing Procedures for Certification of Laboratory Fume Hoods Appendix F: Semi-annual Preventative Maintenance Plan for Laboratory Fume Hoods. Appendix G: Recommendations for New Laboratory Hoods Appendix H: Occupational exposure to hazardous chemicals in laboratories. Appendix K: Permissible Exposure Limits Appendix L: Lists of select carcinogens and substances of high toxicity 2 University of Maine at Presque Isle: Chemical Hygiene Plan I. Purpose and Scope The University of Maine at Presque Isle is committed to providing a safe and healthy environment for all members of the Laboratory community and to reducing the incidence of disease and injury to the lowest achievable level. This Chemical Hygiene Plan (CHP) is specific for the University of Maine at Presque Isle and is in compliance with the Department of Labor Occupational Safety and Health Administrations (OSHA) published final rule for occupational exposure to hazardous chemicals in laboratories [29 CFR 1910.1450] OSHA Standards 29 CFR The objective of this CHP is to describe the work practices, procedures, personal protective equipment and other equipment that will protect University of Maine employees from harm arising from the storage and use of hazardous chemicals in the laboratory. However, the information in this CHP must be supplemented by laboratory specific information, policies and procedures. This Chemical Hygiene Plan will be reviewed annually. II. Responsibilities University of Maine System Office of Safety and Environmental Management Develop and update as needed a general guidance document outlining the format and subject matter that should be covered as required by pertinent regulations in all laboratory safety plans. Offers technical guidance and assistance to campus Chemical Hygiene Officers. Maintain resources that may be used by individual campuses through the Chemical Hygiene Officer to assist in the implementation of training requirements outlined in this plan. Random inspections of laboratories to ensure laboratory safety plans are in place, effective, and being followed. Conduct safety audits of laboratories on request and make recommendations to improve safety within the laboratory. Regulatory Compliance Officer and Safety and Security Officer- Oversees emergency preparedness and response, as well as regulatory compliance issues including the documentation of training. Reviews the Chemical Hygiene Plan with the Chemical Hygiene Officer annually. University Chemical Hygiene Officer – Ensure each laboratory within the science department has an effective laboratory safety plan that is followed by persons teaching or working in the laboratory on a routine basis. Reviews laboratory safety plans before being implemented and on an annual basis after implementation to ensure they are complete and effective. Ensure proper training is provided as described in this plan. Ensures all 3 laboratory instructors are effectively training students prior to starting any lab work. Maintain documentation as to who has been trained in laboratory safety as required by this plan. Ensure all new personnel, as part of their orientation, have reviewed the laboratory safety plan, understand its requirements, and follow those requirements. Ensure all laboratory personnel have been trained in the proper use of safety equipment (such as laboratory ventilation hoods, fire extinguishers, emergency showers and eyewash stations). See Lab Plan Training Sheet at end of this section. Ensure new lab instructors have been properly equipped with personal protective equipment (if necessary) and trained in its proper use. Advise instructors as to emergency procedures to be used in the event of a fire, spill, toxic release, personal injury, or other accident. In collaboration with Facilities Management, ensure necessary safety and personal protective equipment (such as spill kits, laboratory ventilation hoods, emergency showers and eyewash stations, fire extinguishers, safety shields, safety glasses, proper gloves, respirators, and other necessary apparel) is provided prior to any operation that may require such equipment. Maintain a chemical inventory for the science labs, identify potential hazards posed to instructors, students and lab workers, and provide additional training as needed. Department of Facilities (Physical Plant)- Provide routine maintenance of laboratory safety equipment (such as laboratory ventilation hoods, emergency eyewash and shower stations, and general laboratory ventilation) as needed or on request by the department having such equipment. Provide support in emergency preparedness and in emergency situations. In support of the Chemical Hygiene Officer, provide training to laboratory personnel in the proper use of emergency equipment such as fire extinguishers. Provide training to facilities staff on chemical hygiene and safety, maintain MSDS sheets and other safety information for facilities management activities of areas of the university that are not science laboratories and manage universal waste generated on campus. Inform personnel about special or unusual hazards related to non-routine work. Human Resources Human Resources (HR) maintains records of medical testing and surveillance as required under the Lab Standard, coordinates baseline medical surveillance and manages workers’ compensation claims. Instructors and students Instructors will ensure that students review the laboratory safety plan prior to conducting any laboratory work, are trained in laboratory safety practices and equipment, and sign lab safety agreements. Ensure that laboratory work will be conducted with good safety practices and be prepared in advance for possible accidents by knowing what emergency aids are available and how they are to be used. Advise any new employees or students in the laboratory of the laboratory safety plan, necessary safety equipment, and emergency procedures. Communicate with Chemical Hygiene Officer about chemicals received and placed in inventory and about any hazardous waste that is generated in the laboratory. Correctly label and store hazardous waste produced. Practice good personal safety habits. 4 Officers & Departments: Regulatory Compliance Officer and Safety and Security Officer: FRED THOMAS ____________________ 181 Main St. University of Maine at Presque Isle Presque Isle, ME 04769 207-768-9580 Chemical Hygiene Officer: JUDITH ROE ____________________ 181 Main St. University of Maine at Presque Isle Presque Isle, ME 04769 207-768-9450 (-9446) Facilities Management: JOSEPH MOIR ___________________ 181 Main St. University of Maine at Presque Isle Presque Isle, ME 04769 207-768-9576 Human Resources manager: DORIANNE PRATT ________________ 181 Main St. University of Maine at Presque Isle Presque Isle, ME 04769 207-768-9551 III. LAB SAFETY PLAN The purpose of this plan is to provide a safe laboratory work environment for the employees and students of the University of Maine at Presque Isle. Each plan is intended to: *Protect laboratory employees and students from health hazards associated with the use of hazardous chemicals in our laboratories; and *Assure that our laboratory employees and students are not exposed to substances in excess of the permissible exposure limits (PEL's) as defined by the Occupational Safety and Health Administration (OSHA) and codified in 29 CFR 1910.1000, Table Z-A-A; 1 (https://www.osha.gov/dsg/annotated-pels/) and *Assist with laboratories
Recommended publications
  • Decalin Dehydrogenation for In-Situ Hydrogen Production To
    DECALIN DEHYDROGENATION FOR IN-SITU HYDROGEN PRODUCTION TO INCREASE CATALYTIC CRACKING RATE OF N-DODECANE Thesis Submitted to The School of Engineering of the UNIVERSITY OF DAYTON In Partial Fulfillment of the Requirements for The Degree of Master of Science in Chemical Engineering By Christopher Bruening Dayton, Ohio May, 2018 DECALIN DEHYDROGENATION FOR IN-SITU HYDROGEN PRODUCTION TO INCREASE CATALYTIC CRACKING RATE OF N-DODECANE Name: Bruening, Christopher Robbins APPROVED BY: Matthew J. DeWitt, Ph.D. Donald K. Phelps, Ph.D. Advisory Committee Chairman Committee Member Distinguished Research Engineer Senior Research Chemist University of Dayton Research Institute Air Force Research Laboratory Michael Elsass, Ph.D. Kevin Myers, D.Sc., P.E. Committee Member Committee Member Lecturer Professor Department of Chemical and Materials Department of Chemical and Materials Engineering Engineering Robert J. Wilkens, Ph.D., P.E. Eddy M. Rojas, Ph.D., M.A., P.E. Associate Dean for Research and Innovation Dean, School of Engineering Professor School of Engineering School of Engineering ii ABSTRACT DECALIN DEHYDROGENATION FOR IN-SITU HYDROGEN PRODUCTION TO INCREASE CATALYTIC CRACKING RATE OF N-DODECANE Name: Bruening, Christopher Robbins University of Dayton Advisor: Dr. Matthew J. DeWitt Catalytic cracking of paraffinic hydrocarbons is a widely utilized industrial process, but catalyst deactivation over time requires regeneration or replacement of the catalyst bed. A gaseous hydrogen co-feed can be used to promote hydrocracking and decrease deactivation of the catalyst due to coke formation or active site poisoning. One potential alternative approach to extend the lifetime of a cracking catalyst is to generate molecular hydrogen in-situ via catalytic dehydrogenation of a cycloparaffin.
    [Show full text]
  • Dibasic Acids for Nylon Manufacture
    - e Report No. 75 DIBASIC ACIDS FOR NYLON MANUFACTURE by YEN-CHEN YEN October 1971 A private report by the PROCESS ECONOMICS PROGRAM STANFORD RESEARCH INSTITUTE MENLO PARK, CALIFORNIA CONTENTS INTRODUCTION, ....................... 1 SUMMARY .......................... 3 General Aspects ...................... 3 Technical Aspects ..................... 7 INDUSTRY STATUS ...................... 15 Applications and Consumption of Sebacic Acid ........ 15 Applications and Consumption of Azelaic Acid ........ 16 Applications of Dodecanedioic and Suberic Acids ...... 16 Applications of Cyclododecatriene and Cyclooctadiene .... 17 Producers ......................... 17 Prices ........................... 18 DIBASIC ACIDS FOR MANUFACTURE OF POLYAMIDES ........ 21 CYCLOOLIGOMERIZATIONOF BUTADIENE ............. 29 Chemistry ......................... 29 Ziegler Catalyst ..................... 30 Nickel Catalyst ..................... 33 Other Catalysts ..................... 34 Co-Cyclooligomerization ................. 34 Mechanism ........................ 35 By-products and Impurities ................ 37 Review of Processes .................... 38 A Process for Manufacture of Cyclododecatriene ....... 54 Process Description ................... 54 Process Discussion .................... 60 Cost Estimates ...................... 60 A Process for Manufacture of Cyclooctadiene ........ 65 Process Description ................... 65 Process Discussion .................... 70 Cost Estimates ...................... 70 A Process for Manufacture of Cyclodecadiene
    [Show full text]
  • Efficacy of Different Drugs in Treating Urinary Schistosomiasis
    Ecacy of Different Drugs in Treating Urinary Schistosomiasis: Systematic Review and Network Meta-analysis Huilong Fang XiangNan University Xuli Guo XiangNan University Chuwei Tang XiangNan University Fuchun Chen XiangNan University Ahmed Badr Menoua University Faculty of Medicine Feng Luo XiangNan University Junjie Wang ( [email protected] ) XiangNan University Systematic review update Keywords: Urinary schistosomiasis, Praziquantel, Artesunate, Metrifonate Posted Date: May 1st, 2020 DOI: https://doi.org/10.21203/rs.3.rs-16780/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/12 Abstract Background Praziquantel is the current pillar for morbidity control of schistosomiasis. Artesunate and its derivatives, widely used for malaria treatment, also display antischistosomal activities. This review compares the ecacy of three drugs, namely praziquantel (PZQ), artesunate, and metrifonate in urinary schistosomiasis. Methods Databases were searched for articles comparing the effectiveness of any of the three drugs to other medications or controls in urinary schistosomiasis in children aged 18 or less. Stata software was opted to generate the network meta-analysis. Ecacy (Cure rate and egg reduction rate) was the main outcome measure. Pairwise and network meta-analysis were used to report Odds Ratios (ORs) with either 95% condence interval (CI) for direct comparisons or 95% credible intervals (CrI) for indirect comparisons. Results The SUCRA plot for cure rate revealed that PZQ (SUCRA= 40.4%) was the fourth effective drug after albendazole 400mg (SUCRA= 71.5), metrifonate 5 mg (SUCRA= 62.2%), and metrifonate 10 mg (SUCRA= 59.7). PZQ was only superior to metrifonate 7.5 mg.
    [Show full text]
  • Laxatives for the Management of Constipation in People Receiving Palliative Care (Review)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UCL Discovery Laxatives for the management of constipation in people receiving palliative care (Review) Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2015, Issue 5 http://www.thecochranelibrary.com Laxatives for the management of constipation in people receiving palliative care (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 4 METHODS ...................................... 4 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 13 AUTHORS’CONCLUSIONS . 14 ACKNOWLEDGEMENTS . 14 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 17 DATAANDANALYSES. 26 ADDITIONALTABLES. 26 APPENDICES ..................................... 28 WHAT’SNEW..................................... 35 HISTORY....................................... 35 CONTRIBUTIONSOFAUTHORS . 36 DECLARATIONSOFINTEREST . 36 SOURCESOFSUPPORT . 36 DIFFERENCES
    [Show full text]
  • Organic Contaminant Analytical Methods of the National Status and Trends Program: 2000-2006
    Organic Contaminant Analytical Methods of the National Status and Trends Program: 2000-2006 NOAA Technical Memorandum NOS NCCOS 30 Mention of trade names or commercial products does not constitute endorsement or recommendation for their use by the United States government. Cover photograph of shrimping fleet, Palacios, TX Citation for this Report Kimbrough, K. L., G. G. Lauenstein and W. E. Johnson (Editors). 2006. Organic Contaminant Analytical Methods of the National Status and Trends Program: Update 2000-2006. NOAA Technical Memorandum NOS NCCOS 30. 137 pp. Organic Contaminant Analytical Methods of the National Status and Trends Program: Update 2000-2006 K. L. Kimbrough, G. G. Lauenstein and W. E. Johnson (Editors) Center for Coastal Monitoring and Assessment NOAA/NOS/NCCOS 1305 East-West Highway Silver Spring, Maryland 20910 NOAA Technical Memorandum NOS NCCOS 30 June 2007 United States Department of National Oceanic and National Ocean Service Commerce Atmospheric Administration Carlos M. Gutierrez Conrad C. Lautenbacher, Jr. John H. Dunnigan Secretary Administrator Assistant Administrator TABLE OF CONTENTS TABLE OF CONTENTS ..................................................................................................I LIST OF TABLES ..........................................................................................................III LIST OF FIGURES ........................................................................................................IV CHAPTER 1. INTRODUCTION...................................................................................
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Managing Constipation in Adults
    Managing Constipation in Adults Opio id Induced Constipation ● Use an osmotic laxative (or docusate which also softens stools and a stimulant laxative (consider dantron in terminally ill patients). • Treat any underlying causes of condition (e.g. hypothyroidism, haemorrhoids or anal fissures) ● Naloxegol is recommended by NICE TA345 as an option when opioid induced constipation has not adequately responded to laxatives. • Consider Red Flags (See Box A ) An inadequate response is defined as opioid-induced of at least moderate severity in at least 1of the 4 stool symptoms domain (i.e. incomplete bowel movement, hard stool, straining or false alarm) Review medication –consider stopping any medication that may be causing constipation (see Box B ) whilst taking1 laxative class for at least 4 days during the prior 2 weeks. ● Avoid bulk -forming l axatives for treating opioid induced constipation Acute Constipation Chronic Constipation ● Check for faecal loading and manage appropriately Lifestyle advise -to increase fibre in diet (see Box C ), adequate fluid and exercise ● Set realistic expectations for the results of treatment of chronic constipation. Chronic Constipation: First Line treatment • Adjust the dose, choice, and combination of laxative according to symptoms, speed with which Bulk forming laxatives i.e. ispaghula. relief is required, response to treatment, and individual preference. • Ensure adequate fluid intake (caution- frail elderly patients) • The dose of laxative should be gradually titrated upwards (or downwards) to produce one or two • May take several days to act- so not suitable if rapid relief required. soft, formed stools per day. • Not appropriate for opiod induced constipation. • If at least two laxatives (from different classes) have been tried at the highest tolerated recommended doses for at least 6 months, consider the use of prucalopride in women only and lubiprostone for adults with chronic idiopathic constipation.
    [Show full text]
  • Research on Crystal Growth and Characterization at the National Bureau of Standards January to June 1964
    NATL INST. OF STAND & TECH R.I.C AlllDS bnSflb *^,; National Bureau of Standards Library^ 1*H^W. Bldg Reference book not to be '^sn^ t-i/or, from the library. ^ecknlccil v2ote 251 RESEARCH ON CRYSTAL GROWTH AND CHARACTERIZATION AT THE NATIONAL BUREAU OF STANDARDS JANUARY TO JUNE 1964 U. S. DEPARTMENT OF COMMERCE NATIONAL BUREAU OF STANDARDS tiona! Bureau of Standards NOV 1 4 1968 151G71 THE NATIONAL BUREAU OF STANDARDS The National Bureau of Standards is a principal focal point in the Federal Government for assuring maximum application of the physical and engineering sciences to the advancement of technology in industry and commerce. Its responsibilities include development and maintenance of the national stand- ards of measurement, and the provisions of means for making measurements consistent with those standards; determination of physical constants and properties of materials; development of methods for testing materials, mechanisms, and structures, and making such tests as may be necessary, particu- larly for government agencies; cooperation in the establishment of standard practices for incorpora- tion in codes and specifications; advisory service to government agencies on scientific and technical problems; invention and development of devices to serve special needs of the Government; assistance to industry, business, and consumers in the development and acceptance of commercial standards and simplified trade practice recommendations; administration of programs in cooperation with United States business groups and standards organizations for the development of international standards of practice; and maintenance of a clearinghouse for the collection and dissemination of scientific, tech- nical, and engineering information. The scope of the Bureau's activities is suggested in the following listing of its four Institutes and their organizational units.
    [Show full text]
  • COMPASS Therapeutic Notes on the Management of Chronic Constipation in Primary Care
    COMPASS Therapeutic Notes on the Management of Chronic Constipation in Primary Care In this issue: Glossary Page Chronic Constipation lasting longer than 3 months Introduction and background 1 constipation Drugs used in the management of Functional Chronic constipation without a known cause. Also known as primary 3 chronic constipation constipation constipation or idiopathic constipation Bulk-forming laxatives 4 Gastrocolic The occurrence of peristalsis following the entrance of food into the Osmotic laxatives 5 response empty stomach Stimulant laxatives 6 IBS Irritable Bowel Syndrome IBS-C Irritable Bowel Syndrome with Constipation Faecal softeners 7 Melanosis Dark brownish black pigmentation of the mucous membrane of the colon Peripheral opioid-receptor 7 coli due to the deposition of pigment in macrophages antagonists Myenteric Part of the enteric nervous system with an important role in regulating 5HT4 – receptor agonists 7 plexus gut motility Managing constipation in 8 NNT Number Needed to Treat pregnancy and breastfeeding OTC Over The Counter RCT Randomised Controlled Trial Secondary Constipation caused by a drug or medical condition. Secondary constipation constipation is also known as organic constipation SmPC Summary of Product Characteristics A twisting or looping of the bowel resulting in obstruction; can be life- Volvulus threatening Successful completion of the assessment questions at the end of this issue will provide you with 2 hours towards your CPD/CME requirements. Further copies of this and any other edition in the
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • United States Patent Office Patented
    2,826,604 United States Patent Office Patented. Mar. 11, 1958 2 (130-140 C.), the decalyl acetate being recoverable from the reaction mixture by distillation of the neutralized re 2,826,604 action liquid. The recovered product was a straw-colored PREPARATION OF DECAHYDRONAPHTHYL fragrant oil, which was established to be 1-decallyl acetate. ACETATE 5 The position of the acetoxy group was determined by William E. Erner, Wilmington, Del, assignor to Houdry hydrolysis of the ester to the alcohol and subsequent Process Corporation, Wilmington, Del, a corporation conversion to decalone-1 by chromic acid-acetic acid oxi of Delaware dation. - The aceto-oxidation of Decalin can be carried out No Drawing. Application June 2, 1955 10 in the presence of oxidation catalysts of the type em Serial No. 512,853 bodied in the metal salts of the lower fatty acids. Cobalt 2 Claims. (C. 260-488) acetate proved outstanding among the metallic-soap oxi dation catalysts studied. The use of benzoyl peroxide at the start of the process has been found advantageous The present invention relates to the preparation of 1 5 in decreasing the induction period and in giving uni decahydronaphthyl alcohols and the corresponding acetic formly high yields. acid ester and ketone derivatives of Said alcohols. The ratios of Decalin - to acetic anhydride in the oper More particularly the invention is concerned with the ation of the process are not critical, but practical con production of saturated polynuclear carbocyclic com siderations favor the use of at least one-half mol of pounds of the type 20 acetic anhydride per mol of Decalin.
    [Show full text]
  • National Institute for Clinical Excellence
    Appendix C NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Lubiprostone for treating opioid-induced constipation in people with chronic, non-cancer pain Matrix of consultees and commentators Consultees Commentators (no right to submit or appeal) Manufacturers/sponsors General Sucampo Pharma Europe Allied Health Professionals Federation (lubiprostone) Board of Community Health Councils in Wales Patient/carer groups British National Formulary Action on Pain Care Quality Commission Afiya Trust Commissioning Support Appraisals Black Health Agency Service Bladder and Bowel Foundation Department of Health, Social Services Equalities National Council and Public Safety for Northern Ireland Muslim Council of Britain Healthcare Improvement Scotland Muslim Health Network Medicines and Healthcare products Pain Concern Regulatory Agency Pain Relief Foundation National Association of Primary Care Pain UK National Pharmacy Association PromoCon NHS Alliance South Asian Health Foundation NHS Commercial Medicines Unit Specialised Healthcare Alliance NHS Confederation IBS Network Public Health Wales NHS Trust Scottish Medicines Consortium Professional groups Association of Coloproctology of Great Comparator manufacturers Britain and Ireland Abbott Laboratories UK (lactulose) Association for Continence Advice Actavis UK (glycerol suppositories), Association for Palliative Medicine Amdipharm (methylcellulose) British Geriatrics Society Bell Sons & Co (Druggists) Limited British Pain
    [Show full text]